6 brokers have issued 1-year price targets for Savara's shares. Their forecasts range from $1.00 to $17.00. On average, they anticipate Savara's stock price to reach $8.60 in the next twelve months. This suggests a possible upside of 377.8% from the stock's current … Savara Inc. Stock Price (SVRA) | Barron's View today's stock price, news and analysis for Savara Inc. (SVRA). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more. Savara Inc. Common Stock (SVRA) Analyst Research | Nasdaq Find the latest analyst research for Savara Inc. Common Stock (SVRA) at Nasdaq.com. Looking for additional market data? The average price target is $ 0.00 with a high estimate of $ 0.00 and a
SVRA Stock Price, Forecast & News (Savara) | MarketBeat
Premarket analyst action - healthcare - Savara Inc ... Sep 22, 2017 · Savara (SVRA) initiated with Buy rating and $20 (111% upside) price target by Jefferies. Madrigal Pharmaceuticals (MDGL) initiated with Outperform rating a Read This Before Selling Savara Inc. (NASDAQ:SVRA) Shares ... Apr 26, 2019 · See our latest analysis for Savara Savara Insider Transactions Over The Last Year In the last twelve months, the biggest single purchase by an insider was when Co-Founder Robert Neville bought US$150k worth of shares at a price of US$6.38 per share. Savara Price | Markets Insider
Savara Inc., formerly Mast Therapeutics, Inc., is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex, AeroVanc and Aironite.
Apr 03, 2020 · SVRA: Get the latest Savara stock price and detailed information including SVRA news, historical charts and realtime prices. Savara (NasdaqGS:SVRA) - Share price, News & Analysis ... Savara Inc. operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; and in Phase IIa development stage for treating nontuberculous mycobacterial lung infection. SAVARA INC. : SVRA Stock Price | MarketScreener
Information on stock, financials, earnings, subsidiaries, investors, and executives for Savara. Use the PitchBook Platform to explore the full profile.
Check out our SVRA stock analysis, current SVRA quote, charts, and historical prices for Savara Inc stock Savara Inc. Stock Price and News, Technical and ... Get a daily update on SVRA stock. Find out current SVRA stock price including technical and fundamental analysis of the stock, powered by AI. Savara Inc. Stock Price and News, Technical and Fundamental Analysis, Daily. A.I.dvisor analyzed 140 other stocks in the Pharmaceuticals: Major Industry for the month ending November 29, 2019, Savara Pharmaceuticals - IPO & Stock Price | Crunchbase Jun 01, 2017 · Savara Pharmaceuticals > IPO & Stock Price . Follow . COMPARE. Edit . IPO & Stock Price . Profile Sections. Overview Lists Featuring This Company M&A Details IPO & Stock Price Funding Rounds Investors Acquisitions Company Tech Stack by Siftery Website Tech Stack by BuiltWith Web Traffic by SimilarWeb Patents and Trademarks by IPqwery Current Premarket analyst action - healthcare - Savara Inc ...
Savara Price: This is the Price-site for the company Savara on Markets Insider
Quote. Last Trade, $2.03. Date, April 6, 2020 4:00 PM EST. Change (%), 0%. Savara Inc. Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization 23 Mar 2020 Real-time trade and investing ideas on Savara Inc SVRA from the largest community of traders and investors.
Get the latest Savara, Inc. (SVRA) stock news and headlines to help you in your trading and investing decisions. Fair Value is the appropriate price for the shares of a company, based on its